Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
ResMed Inc(RMD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RMD
11/10/2026: RMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
ResMed is a leading medical device company known for its cloud-connected sleep therapy hardware and growing software-as-a-service (SaaS) business. The company maintains a strong position in the sleep-disordered breathing market by combining essential medical hardware with data-driven patient monitoring services. Its primary growth opportunity lies in increasing global awareness of sleep health and scaling its digital platform to capture more of the home-care journey. Investors should monitor risks related to hardware competition, regulatory compliance, and potential technological shifts in therapy. The stock is often considered a fit for growth and dividend-oriented investors seeking exposure to the digital transformation of home-based medical care.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The expansion into digital health and recurring SaaS revenue provides a sustainable long-term growth narrative. |
| Momentum investor | Mixed fit | Performance is subject to cyclical demand and regulatory developments, requiring active monitoring of upturn signals. |
| Value investor | Mixed fit | The stock often trades at a premium multiple due to its market-leading position and steady cash flows. |
| Dividend investor | Strong fit | Consistent dividend payouts combined with capital appreciation potential make it a reliable choice for income-focused investors. |
| Low-risk investor | Strong fit while signal remains positive | The company's essential-care business model and strong balance sheet provide stability relative to more speculative medical device companies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock can experience shifts based on market sentiment toward the medical device sector and broader economic conditions. |
| Valuation risk | Medium | Investors should be mindful of premium earnings multiples that may be sensitive to earnings growth deceleration. |
| Competition risk (Hardware/SaaS) | Medium / high | Increased pressure from rivals and non-traditional players in digital health could impact market share and pricing power. |
| Business quality | Strong | The company’s high-margin, recurring revenue business model provides a stable foundation for long-term operations. |
| Dividend income | Low | While consistent, dividends are modest and should be viewed as a supplemental return rather than a primary yield play. |
| Execution risk | Medium | Successful integration of acquired SaaS businesses and maintaining quality standards across global manufacturing is essential. |
Price Behavior
Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -17.13% | Avg. Invested days 40 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/10/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 33.16B USD | Price to earnings Ratio 21.47 | 1Y Target Price 264.33 |
Price to earnings Ratio 21.47 | 1Y Target Price 264.33 | ||
Volume (30-day avg) 1.3M shares | Beta 0.76 | 52 Weeks Range 179.75 - 275.42 | Updated Date 11/10/2026 |
52 Weeks Range 179.75 - 275.42 | Updated Date 11/10/2026 | ||
Dividends yield (FY) 1.05% | Basic EPS (TTM) 10.98 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Sleep and Respiratory Devices | CPAP machines, masks, and tubing. | Hardware sales drive immediate revenue and create the installed base for recurring accessories. |
| SaaS and Digital Health | Brightree and MatrixCare software subscriptions. | Subscription fees provide steady, higher-margin recurring revenue that smooths out hardware sales volatility. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When After Market | Estimate 2.67 | Actual 2.91 |
Profitability
Profit Margin 27.79% | Operating Margin (TTM) 34.82% |
Management Effectiveness
Return on Assets (TTM) 14.76% | Return on Equity (TTM) 26.4% |
Valuation
Trailing PE 21.47 | Forward PE 19.61 | Enterprise Value 32.70B | Price to Sales(TTM) 5.78 |
Enterprise Value 32.70B | Price to Sales(TTM) 5.78 | ||
Enterprise Value to Revenue 5.7 | Enterprise Value to EBITDA 14.62 | Shares Outstanding 140.66M | Shares Floating 139.83M |
Shares Outstanding 140.66M | Shares Floating 139.83M | ||
Percent Insiders 0.51 | Percent Institutions 72.54 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.